ReportGem ReportGem

U.S. COMPANY FILING

REGENERON PHARMACEUTICALS, INC. — Form 10-Q filed 2025-10-28

Filed: 2025-10-28Company: REGENERON PHARMACEUTICALS, INC.Ticker: REGNExchange: NasdaqForm: 10-QReport period: 2025-09-30SEC accession: 0000872589-25-000028Event: earningsMateriality: 85

Filing text preview

Regeneron's Q3 2025 net income rose 9% to $1.46B, with total revenue up 1% to $3.75B. EYLEA U.S. sales fell 41% due to biosimilar competition, while EYLEA HD and Libtayo grew. Sanofi collaboration revenue increased 28%. The company declared a $0.88 dividend and continued buybacks. Risks include EYLEA biosimilars and Dupixent dependence.

This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.

Open filing record

Related research and intelligence

Official SEC filing2025-10-28Why Regeneron (REGN) Is Up 5.4% After FDA Approves Pasatru For Ultra-Rare FOP Therapy2026-08-20FDA Approves Regeneron's (REGN) Pasatru for Ultra-Rare FOP in August 2026; Shares Up 5.4%2026-08-2010-Q2026-07-30 · 10-Q8-K2026-07-30 · 8-K10-Q2026-04-29 · 10-Q8-K2026-04-29 · 8-K10-K2026-02-04 · 10-K